Therefore, we found that BTK was overexpressed in the majority of the MCL patients with high Ki67 and MIPI scores, suggesting that the strategy of specifically inhibiting BTK has a promising clinical value for treating MCL. This evidence concerns the gene MKI67 and mantle cell lymphoma.